Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23


Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.

Ritter A, Cummings J.

Front Neurol. 2015 Aug 31;6:186. doi: 10.3389/fneur.2015.00186. eCollection 2015. Review.


Platelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease.

Plagg B, Marksteiner J, Kniewallner KM, Humpel C.

Biogerontology. 2015 Aug;16(4):543-58. doi: 10.1007/s10522-015-9580-1. Epub 2015 May 7.


Potential natural products for Alzheimer's disease: targeted search using the internal ribosome entry site of tau and amyloid-β precursor protein.

Tasi YC, Chin TY, Chen YJ, Huang CC, Lee SL, Wu TY.

Int J Mol Sci. 2015 Apr 20;16(4):8789-810. doi: 10.3390/ijms16048789.


Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study.

Hertze J, Nägga K, Minthon L, Hansson O.

BMC Neurol. 2014 Apr 1;14:64. doi: 10.1186/1471-2377-14-64.


Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

Ansari N, Khodagholi F.

Curr Neuropharmacol. 2013 Jul;11(4):414-29. doi: 10.2174/1570159X11311040005.


Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1-42-infused mouse model of Alzheimer's disease.

Yun HM, Kim HS, Park KR, Shin JM, Kang AR, il Lee K, Song S, Kim YB, Han SB, Chung HM, Hong JT.

Cell Death Dis. 2013 Dec 12;4:e958. doi: 10.1038/cddis.2013.490.


Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.

Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C.

Exp Gerontol. 2014 Feb;50:114-21. doi: 10.1016/j.exger.2013.12.001. Epub 2013 Dec 10.


Role of copper and cholesterol association in the neurodegenerative process.

Arnal N, Morel GR, de Alaniz MJ, Castillo O, Marra CA.

Int J Alzheimers Dis. 2013;2013:414817. doi: 10.1155/2013/414817. Epub 2013 Oct 29.


Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.

Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa IT, Przybylski M, Manea M, von Arnim CA.

PLoS One. 2013 Jul 18;8(7):e68996. doi: 10.1371/journal.pone.0068996. Print 2013.


Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.

Moreth J, Mavoungou C, Schindowski K.

Front Aging Neurosci. 2013 Jul 2;5:25. doi: 10.3389/fnagi.2013.00025. eCollection 2013.


Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH.

Malm J, Graff-Radford NR, Ishikawa M, Kristensen B, Leinonen V, Mori E, Owler BK, Tullberg M, Williams MA, Relkin NR.

Fluids Barriers CNS. 2013 Jun 10;10(1):22. doi: 10.1186/2045-8118-10-22.


Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flow.

Choi YJ, Chae S, Kim JH, Barald KF, Park JY, Lee SH.

Sci Rep. 2013;3:1921. doi: 10.1038/srep01921.


Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease.

Hertze J, Palmqvist S, Minthon L, Hansson O.

Dement Geriatr Cogn Dis Extra. 2013 Apr 19;3(1):113-22. doi: 10.1159/000348353. Print 2013 Jan.


Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.

Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Månsson JE, Porter FD, Blennow K.

JIMD Rep. 2012;3:45-52. doi: 10.1007/8904_2011_47. Epub 2011 Sep 28.


Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro.

Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Yang HC, Chen KH, Shih BY, Chen TF, Chiu MJ.

ACS Chem Neurosci. 2011 Sep 21;2(9):500-5. doi: 10.1021/cn200028j. Epub 2011 May 30.


Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder.

Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, Zetterberg H, Blennow K.

Am J Psychiatry. 2012 May;169(5):523-30.


The "Alzheimer's disease signature": potential perspectives for novel biomarkers.

Davinelli S, Intrieri M, Russo C, Di Costanzo A, Zella D, Bosco P, Scapagnini G.

Immun Ageing. 2011 Sep 20;8:7. doi: 10.1186/1742-4933-8-7.


Identifying and validating biomarkers for Alzheimer's disease.

Humpel C.

Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23. Review.


Regulation of amyloid precursor protein processing by the Beclin 1 complex.

Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E, Wyss-Coray T.

PLoS One. 2010 Jun 15;5(6):e11102. doi: 10.1371/journal.pone.0011102.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk